Update shared on 13 Dec 2025
Fair value Increased 1.69%Narrative Update on Krishna Institute of Medical Sciences
Analysts have raised their price target on Krishna Institute of Medical Sciences from ₹885 to ₹900, citing expectations of stronger profit margins and a slightly lower future valuation multiple. These factors more than offset marginally softer revenue growth assumptions and a modestly higher discount rate.
What's in the News
- A board meeting is scheduled for November 7, 2025, to consider and approve the unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing).
Valuation Changes
- Fair Value: Risen slightly from ₹885 to ₹900, reflecting a modestly higher intrinsic valuation.
- Discount Rate: Increased marginally from 12.73% to 12.76%, indicating a slightly higher required return assumption.
- Revenue Growth: Eased slightly from 30.91% to 30.63%, implying a small moderation in top line growth expectations.
- Net Profit Margin: Improved from 15.04% to 15.61%, indicating a moderate upgrade in profitability assumptions.
- Future P/E: Fallen moderately from 46.71x to 43.72x, suggesting a lower valuation multiple applied to forward earnings.
Have other thoughts on Krishna Institute of Medical Sciences?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.